{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:39:32Z","timestamp":1795045172717,"version":"4.10.2"},"reference-count":55,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,5,16]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Imatinib does not prevent accumulation of genomic instability in CML-CP. Imatinib-refractory leukemia stem cells may be a source of genomic instability in CML-CP.<\/jats:p>","DOI":"10.1182\/blood-2012-11-466938","type":"journal-article","created":{"date-parts":[[2013,3,30]],"date-time":"2013-03-30T01:21:24Z","timestamp":1364606484000},"page":"4175-4183","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":120,"title":["Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells"],"prefix":"10.1182","volume":"121","author":[{"given":"Elisabeth","family":"Bolton-Gillespie","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, School of Medicine, Temple University, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirle","family":"Schemionek","sequence":"additional","affiliation":[{"name":"Department of Medicine (Oncology, Hematology, and Stem Cell Transplantation), University Medical Center of Aachen, Aachen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Klein","sequence":"additional","affiliation":[{"name":"Institute of Medical Informatics, University of M\u00fcnster, M\u00fcnster, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Flis","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, School of Medicine, Temple University, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazyna","family":"Hoser","sequence":"additional","affiliation":[{"name":"Department of Clinical Cytology, Medical Center for Postgraduate Education, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thoralf","family":"Lange","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr H\u00e4matologie, Onkologie, H\u00e4mostaseologie, Universit\u00e4tsklinikum Leipzig, Leipzig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Nieborowska-Skorska","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, School of Medicine, Temple University, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Maier","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr H\u00e4matologie, Onkologie, H\u00e4mostaseologie, Universit\u00e4tsklinikum Leipzig, Leipzig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Kerstiens","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of M\u00fcnster, M\u00fcnster, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Koptyra","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, School of Medicine, Temple University, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik","family":"Modi","sequence":"additional","affiliation":[{"name":"Division of Hematopoietic Stem Cell and Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Stoklosa","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical University of Warsaw, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Seferynska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology and Blood Transfusion, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Division of Hematopoietic Stem Cell and Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukemia Research Centre, University of Glasgow, Glasgow, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[{"name":"Department of Medicine (Oncology, Hematology, and Stem Cell Transplantation), University Medical Center of Aachen, Aachen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Skorski","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, School of Medicine, Temple University, Philadelphia, PA;"},{"name":"Fels Institute for Cancer Research and Molecular Biology, School of Medicine, Temple University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111616463018400_B1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer.","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2019111616463018400_B2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1741-7015-9-99","article-title":"Advances in the treatment of chronic myeloid leukemia.","volume":"9","author":"Eiring","year":"2011","journal-title":"BMC Med"},{"issue":"1","key":"2019111616463018400_B3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111616463018400_B4","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation.","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111616463018400_B5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1096\/fj.02-0752rev","article-title":"Oxidative DNA damage: mechanisms, mutation, and disease.","volume":"17","author":"Cooke","year":"2003","journal-title":"FASEB J"},{"key":"2019111616463018400_B6","doi-asserted-by":"crossref","DOI":"10.1038\/nrc1046","article-title":"Radical causes of cancer.","volume-title":"Nat Rev Cancer","author":"Hussain","year":"2003"},{"issue":"18","key":"2019111616463018400_B7","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","article-title":"Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.","volume":"119","author":"Nieborowska-Skorska","year":"2012","journal-title":"Blood"},{"key":"2019111616463018400_B8","author":"Koptyra"},{"issue":"1","key":"2019111616463018400_B9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111616463018400_B10","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/leu.2008.210","article-title":"Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis.","volume":"22","author":"Khorashad","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"2019111616463018400_B11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cancergencyto.2004.06.011","article-title":"Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression.","volume":"157","author":"Bacher","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"2019111616463018400_B12","author":"Willis"},{"key":"2019111616463018400_B13","author":"Soverini"},{"issue":"11","key":"2019111616463018400_B14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/gcc.20487","article-title":"Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression.","volume":"46","author":"Brazma","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2019111616463018400_B15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases.","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"2019111616463018400_B16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/leu.2009.222","article-title":"Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment.","volume":"24","author":"Haferlach","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"2019111616463018400_B17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2009-03-210377","article-title":"SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations [published correction appears Blood. 2010;115(19):4006.].","volume":"115","author":"Nowak","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111616463018400_B18","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/j.1349-7006.2010.01627.x","article-title":"Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.","volume":"101","author":"Yin","year":"2010","journal-title":"Cancer Sci"},{"issue":"9","key":"2019111616463018400_B19","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.","volume":"99","author":"Jiang","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2019111616463018400_B20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/leu.2010.197","article-title":"Do we have to kill the last CML cell?","volume":"25","author":"Ross","year":"2011","journal-title":"Leukemia"},{"key":"2019111616463018400_B21","author":"Chu"},{"key":"2019111616463018400_B22","author":"Koschmieder"},{"issue":"16","key":"2019111616463018400_B23","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1182\/blood-2009-04-215376","article-title":"BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.","volume":"115","author":"Schemionek","year":"2010","journal-title":"Blood"},{"key":"2019111616463018400_B24","author":"Nowicki"},{"issue":"12","key":"2019111616463018400_B25","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.4161\/cc.4.12.2261","article-title":"BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?","volume":"4","author":"Lange","year":"2005","journal-title":"Cell Cycle"},{"issue":"3","key":"2019111616463018400_B26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ajh.22272","article-title":"BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.","volume":"87","author":"Alikian","year":"2012","journal-title":"Am J Hematol"},{"issue":"17","key":"2019111616463018400_B27","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/bioinformatics\/btp371","article-title":"A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6.","volume":"25","author":"Bengtsson","year":"2009","journal-title":"Bioinformatics"},{"issue":"6","key":"2019111616463018400_B28","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/wsbm.86","article-title":"Hematopoietic stem cell: self-renewal versus differentiation.","volume":"2","author":"Seita","year":"2010","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"19","key":"2019111616463018400_B29","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1182\/blood-2007-05-088724","article-title":"Enhanced expression of p210BCR\/ABL and aberrant expression of Zfp423\/ZNF423 induce blast crisis of chronic myelogenous leukemia.","volume":"113","author":"Miyazaki","year":"2009","journal-title":"Blood"},{"issue":"7191","key":"2019111616463018400_B30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"21","key":"2019111616463018400_B31","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"issue":"14","key":"2019111616463018400_B32","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.1073\/pnas.88.14.6293","article-title":"p53 in chronic myelogenous leukemia in acute phase.","volume":"88","author":"Feinstein","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2019111616463018400_B33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.leukres.2010.07.012","article-title":"Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients.","volume":"35","author":"Joha","year":"2011","journal-title":"Leuk Res"},{"issue":"28","key":"2019111616463018400_B34","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1038\/onc.2009.119","article-title":"PAK signaling in oncogenesis.","volume":"28","author":"Molli","year":"2009","journal-title":"Oncogene"},{"issue":"4","key":"2019111616463018400_B35","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.chembiol.2008.03.005","article-title":"An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.","volume":"15","author":"Deacon","year":"2008","journal-title":"Chem Biol"},{"issue":"2","key":"2019111616463018400_B36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.leukres.2009.09.026","article-title":"A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia.","volume":"34","author":"de Lavallade","year":"2010","journal-title":"Leuk Res"},{"issue":"8","key":"2019111616463018400_B37","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.leu.2404270","article-title":"Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.","volume":"20","author":"Frank","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2019111616463018400_B38","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/cncr.26391","article-title":"Suboptimal responses in chronic myeloid leukemia: implications and management strategies.","volume":"118","author":"Jabbour","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"2019111616463018400_B39","doi-asserted-by":"crossref","first-page":"e33499","DOI":"10.1371\/journal.pone.0033499","article-title":"A sensitive and quantitative polymerase chain reaction-based cell free in vitro non-homologous end joining assay for hematopoietic stem cells.","volume":"7","author":"Shao","year":"2012","journal-title":"PLoS ONE"},{"issue":"4","key":"2019111616463018400_B40","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia.","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"issue":"19","key":"2019111616463018400_B41","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"issue":"7","key":"2019111616463018400_B42","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111616463018400_B43","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111616463018400_B44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.stem.2010.06.014","article-title":"Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis.","volume":"7","author":"Mohrin","year":"2010","journal-title":"Cell Stem Cell"},{"key":"2019111616463018400_B45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-4598-10-41","article-title":"Expression patterns of microRNAs associated with CML phases and their disease related targets.","volume":"10","author":"Machov\u00e1 Pol\u00e1kov\u00e1","year":"2011","journal-title":"Mol Cancer"},{"issue":"9","key":"2019111616463018400_B46","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1182\/blood.V93.9.2928","article-title":"Hematopoietic growth factors signal through the formation of reactive oxygen species.","volume":"93","author":"Sattler","year":"1999","journal-title":"Blood"},{"issue":"6","key":"2019111616463018400_B47","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccr.2011.05.007","article-title":"Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.","volume":"19","author":"Schmidt","year":"2011","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111616463018400_B48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/12963","article-title":"Activation of LIM-kinase by Pak1 couples Rac\/Cdc42 GTPase signalling to actin cytoskeletal dynamics.","volume":"1","author":"Edwards","year":"1999","journal-title":"Nat Cell Biol"},{"issue":"Pt 20","key":"2019111616463018400_B49","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1242\/jcs.01339","article-title":"Beta-actin is required for mitochondria clustering and ROS generation in TNF-induced, caspase-independent cell death.","volume":"117","author":"Li","year":"2004","journal-title":"J Cell Sci"},{"issue":"3","key":"2019111616463018400_B50","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.bbrc.2004.08.169","article-title":"Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia.","volume":"323","author":"Sorel","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2019111616463018400_B51","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"issue":"8","key":"2019111616463018400_B52","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia.","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2019111616463018400_B53","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/leu.2008.65","article-title":"Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.","volume":"22","author":"Sherbenou","year":"2008","journal-title":"Leukemia"},{"issue":"20","key":"2019111616463018400_B54","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111616463018400_B55","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/20\/4175\/531136\/4175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/20\/4175\/531136\/4175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T21:46:45Z","timestamp":1573940805000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/20\/4175\/116546\/Genomic-instability-may-originate-from"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,16]]},"references-count":55,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2013,5,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-11-466938","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,16]]}}}